Literature DB >> 17517849

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

A H Diacon1, R F Patientia, A Venter, P D van Helden, P J Smith, H McIlleron, J S Maritz, P R Donald.   

Abstract

We studied the early bactericidal activity of twice the standard dose of rifampin in subjects with pulmonary tuberculosis evidenced by positive smears. The observed mean 2-day activity was almost double that reported at the standard dose. Further studies are warranted to establish whether higher rifampin doses might assist in shortening tuberculosis treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17517849      PMCID： PMC1932511          DOI： 10.1128/AAC.01474-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Two three-month treatment regimens for pulmonary tuberculosis.

Authors:  B Kreis; S Pretet; J Birenbaum; P Guibout; J J Hazeman; E Orin; S Perdrizet; J Weil
Journal:  Bull Int Union Tuberc       Date:  1976

2.  What is the 'right' dose of rifampin?

Authors:  Charles Peloquin
Journal:  Int J Tuberc Lung Dis       Date:  2003-01       Impact factor: 2.373

3.  Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood.

Authors:  L Verbist; A Gyselen
Journal:  Am Rev Respir Dis       Date:  1968-12

4.  [Jaundice during treatment with rifampicin (12 cases)].

Authors:  R Lesobre; J Ruffino; L Teyssier; F Achard; G Brefort
Journal:  Rev Tuberc Pneumol (Paris)       Date:  1969 Apr-May

5.  Jaundice after rifampicin.

Authors:  A W Lees; B Asgher; M A Hashem; B N Sinha
Journal:  Br J Dis Chest       Date:  1970-04

Review 6.  An official ATS statement: hepatotoxicity of antituberculosis therapy.

Authors:  Jussi J Saukkonen; David L Cohn; Robert M Jasmer; Steven Schenker; John A Jereb; Charles M Nolan; Charles A Peloquin; Fred M Gordin; David Nunes; Dorothy B Strader; John Bernardo; Raman Venkataramanan; Timothy R Sterling
Journal:  Am J Respir Crit Care Med       Date:  2006-10-15       Impact factor: 21.405

Review 7.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Role of individual drugs in the chemotherapy of tuberculosis.

Authors:  D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2000-09       Impact factor: 2.373

9.  Treatment of chronic drug-resistant pulmonary tuberculosis with rifampin and ethambutol.

Authors:  C W Jeanes; A G Jessamine; L Eidus
Journal:  Can Med Assoc J       Date:  1972-04-22       Impact factor: 8.262

10.  Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.

Authors:  R van Crevel; B Alisjahbana; W C M de Lange; F Borst; H Danusantoso; J W M van der Meer; D Burger; R H H Nelwan
Journal:  Int J Tuberc Lung Dis       Date:  2002-06       Impact factor: 2.373
View more
  81 in total

1.  Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors:  Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Plasma drug activity assay for treatment optimization in tuberculosis patients.

Authors:  Scott K Heysell; Charles Mtabho; Stellah Mpagama; Solomon Mwaigwisya; Suporn Pholwat; Norah Ndusilo; Jean Gratz; Rob E Aarnoutse; Gibson S Kibiki; Eric R Houpt
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 3.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 4.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 5.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 6.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

7.  High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Authors:  Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Stefan V Goldberg; Lorna Bozeman; William J Burman; Kwok-Chiu Chang; Michael Chen; Mark Cotton; Kelly E Dooley; Melissa Engle; Pei-Jean Feng; Courtney V Fletcher; Phan Ha; Charles M Heilig; John L Johnson; Erica Lessem; Beverly Metchock; Jose M Miro; Nguyen Viet Nhung; April C Pettit; Patrick P J Phillips; Anthony T Podany; Anne E Purfield; Kathleen Robergeau; Wadzanai Samaneka; Nigel A Scott; Erin Sizemore; Andrew Vernon; Marc Weiner; Susan Swindells; Richard E Chaisson
Journal:  Contemp Clin Trials       Date:  2020-01-22       Impact factor: 2.226

8.  Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.

Authors:  Alvaro A Ordonez; Hechuan Wang; Gesham Magombedze; Camilo A Ruiz-Bedoya; Shashikant Srivastava; Allen Chen; Elizabeth W Tucker; Michael E Urbanowski; Lisa Pieterse; E Fabian Cardozo; Martin A Lodge; Maunank R Shah; Daniel P Holt; William B Mathews; Robert F Dannals; Jogarao V S Gobburu; Charles A Peloquin; Steven P Rowe; Tawanda Gumbo; Vijay D Ivaturi; Sanjay K Jain
Journal:  Nat Med       Date:  2020-02-17       Impact factor: 53.440

9.  Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Authors:  Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

10.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.